



Transforming PCR for Breakthrough Infectious Disease Testing @ANYWHERE™

CORE TEAM

Kevin Kraus, MBA
Chief Executive Officer

Mark Kelleher, PhD
VP, Research & Development

Jay Foust, MBA
VP, Business Development

Shelle Pourmanafzadehardabili
VP, Business Operations

Barbara Handelin, PhD
Board Member, pioneer in PCR

Russ Hullet
Co-Founder, Board Director

Bob Blomquist
Co-Inventor, Board Chair

KEY ADVISORS

Chuck Henry, PhD
Professor Chemical & Biological
Engineering, CSU

Mickey Urdea, PhD
Diagnostics Advisor & pioneer

INTELLECTUAL PROPERTY

- Landmark US Patent #12,344,889 issued July 2025
- Exclusive rights to IP co-developed with University of Colorado Anschutz
- 5 patents pending including on @ANYWHERE™ device

ASK

\$2.75M SAFE/equity raise

- Expand evidence and utility
- Quality & regulatory systems
- Patent prosecution
- Manufacturing, sales, and partnering
- Handheld device development

PROBLEM

- 14M people die annually from infectious diseases like tuberculosis, respiratory infections, and sexually transmitted infections (STIs).
- People lack access to rapid, accurate, and affordable testing.
- Gold-standard PCR (Polymerase Chain Reaction) testing is stuck in the lab because it is technologically complex.

OUR SOLUTIONS

- Rapid, accurate, and affordable infectious disease testing performed @ANYWHERE.
- Direct-to-PCR technologies that eliminate DNA/RNA purification with novel, non-toxic chemistries.



Simplify conventional PCR



Moving PCR out of the lab with @ANYWHERE device

CLINICALLY VALIDATED

- >590,000 direct-to-PCR patient samples tested in former company, Summit Biolabs, in Colorado.
- Testing enabled by our IP reagent platform: ≥7-day sample stability at 40°C.
- 5-10x faster, 7x lower cost and and turnaround time with same high accuracy compared to conventional PCR.
- Platform works on viruses (COVID, flu) and bacteria (chlamydia, gonorrhea) with further studies planned on challenging pathogens (tuberculosis).

TARGET MARKET OPPORTUNITY

- \$17B target market global molecular diagnostics market (labs and manufacturers), spanning reagents, sample collection, and centralized and point-of-care PCR.
- Drive DirectAmp™ reagent sales beginning with RUO, then IVD (ISO 13485) through wholesalers.
- Establish OEM, channel, and licensing partnerships to scale the @ANYWHERE platform.

IMPACT

- Expand access to PCR testing for infectious diseases outside the lab with @ANYWHERE, enabling earlier detection, faster treatment decisions, and fewer deaths.